# A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

> **NCT04557150** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 225 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Forimtamig

## Key facts

- **NCT ID:** NCT04557150
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-11
- **Primary completion:** 2026-03-17
- **Final completion:** 2026-03-17
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557150, "A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04557150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*